



(51) International Patent Classification:

A61K 39/00 (2006.01) *A61P 11/06* (2006.01)*C07K 16/24* (2006.01) *A61P 13/12* (2006.01)*A61P 11/00* (2006.01) *A61P 17/00* (2006.01)(GB). **ESFANDIARY, Reza**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). **PARUPUDI, Arun**; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US).

(21) International Application Number:

PCT/EP2021/062310

(74) **Agent: ASTRAZENECA INTELLECTUAL PROPERTY**; Milstein Building Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).

(22) International Filing Date:

10 May 2021 (10.05.2021)

(25) Filing Language:


English

(26) Publication Language:

English

(30) Priority Data:

20200100239 11 May 2020 (11.05.2020) GR

(71) **Applicant: MEDIMMUNE LIMITED** [GB/GB]; Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB).(72) **Inventors: EKIZOGLOU, Sofia**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH (GB). **AHMED, Mahammad, Syed, Mastafa**; MedImmune Limited, Milstein Building, Granta Park, Cambridge Cambridgeshire CB21 6GH(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,(54) **Title:** FORMULATIONS OF ANTI-IL-33 ANTIBODIES**Figure 1**(57) **Abstract:** The present disclosure is directed to compositions comprising greater than about 100 mg/ml of an anti-IL-33 antibody, a surfactant, arginine and a buffer. Methods for making the compositions and methods of treating disease in a subject are also disclosed.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*